Defeating Alzheimer's disease and other dementias: a priority for European science and society

Bengt Winblad, Philippe Amouyel, Sandrine Andrieu, Clive Ballard, Carol Brayne, Henry Brodaty, Angel Cedazo-Minguez, Bruno Dubois, David Edvardsson, Howard Feldman, Laura Fratiglioni, Giovanni B. Frisoni, Serge Gauthier, Jean Georges, Caroline Graff, Khalid Iqbal, Frank Jessen, Gunilla Johansson, Linus Jonsson, Miia KivipeltoMartin Knapp, Francesca Mangialasche, Rene Melis, Agneta Nordberg, Marcel Olde Rikkert, Chengxuan Qiu, Thomas P. Sakmar, Philip Scheltens, Lon S. Schneider, Reisa Sperling, Lars O. Tjernberg, Gunhild Waldemar, Anders Wimo, Henrik Zetterberg

Research output: Contribution to journalArticleAcademicpeer-review

Abstract

Alzheimer's disease (AD) is the leading cause of dementia, and because the primary risk factor for AD is old age, the prevalence of the disease is increasing dramatically with ageing populations worldwide. Even in high-income countries, the cost of medical care and associated societal burdens of dementia threaten to become overwhelming as more people live into old age. In view of the lack of progress in developing a cure for AD and the rapidly increasing costs of dementia, policy makers and governments have a powerful incentive to provide more resources to develop AD therapeutics. The Lancet Neurology Commission was formed with the overarching aim to provide information and expert recommendations to policy makers and political leaders about the growing problem of AD and related dementias of ageing.
Original languageEnglish
Pages (from-to)455-532
JournalLancet Neurology
Volume15
Issue number5
DOIs
Publication statusPublished - Apr 2016

Cite this